JS004

DRUG6 trials

Sponsors

Shanghai Junshi Bioscience Co., Ltd., Shanghai Pulmonary Hospital, Shanghai, China, Fudan University

Conditions

Clear Cell Renal Cell CarcinomaLimited Stage Small Cell Lung CancerLiver Cancer, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Cervical Cancer, MSI-H Colorectal CancerPancreatic CancerSmall Cell Lung Cancer Extensive StageSmall Cell Lung Cancer RecurrentStage III Non-small Cell Lung Cancer

Phase 1

A Phase I Clinical Study of Recombinant Humanized Anti-BTLA Monoclonal Antibody (JS004) Injection Combined With Toripalimab Injection in Patients With Advanced Solid Tumors

TerminatedNCT05427396

Shanghai Junshi Bioscience Co., Ltd.Liver Cancer, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Cervical Cancer, MSI-H Colorectal Cancer

Start: 2022-07-28End: 2024-01-15Updated: 2025-12-03

Newly Emerging Immunotherapy for Pancreatic Cancer Treatment

Not yet recruitingNCT06370754

Fudan UniversityPancreatic Cancer

Start: 2024-04-30End: 2027-04-30Target: 117Updated: 2024-04-17

Phase 2

Neoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 Trial

Not yet recruitingNCT05891080

Shanghai Pulmonary Hospital, Shanghai, ChinaStage III Non-small Cell Lung Cancer

Start: 2023-07-01End: 2030-07-01Target: 124Updated: 2023-06-06

Neoadjuvant Therapy With Toripalimab and JS004 Combined With Etoposide and Platinum Chemotherapy for Limited-stage Small Cell Lung Cancer : A Phase 2 Trial

RecruitingNCT06256237

Shanghai Pulmonary Hospital, Shanghai, ChinaLimited Stage Small Cell Lung Cancer

Start: 2024-04-01End: 2032-01-31Target: 30Updated: 2024-05-29

Toripalimab and JS004 Combined With Platinum-based Chemotherapy for Relapsed and Extensive-stage Small Cell Lung Cancer

Not yet recruitingNCT06648200

Shanghai Pulmonary Hospital, Shanghai, ChinaSmall Cell Lung Cancer Extensive Stage, Small Cell Lung Cancer Recurrent

Start: 2024-11-01End: 2030-09-01Target: 100Updated: 2024-10-18

Combination of Toripalimab and JS004 Therapy for ccRCC

RecruitingNCT06690697

Fudan UniversityClear Cell Renal Cell Carcinoma

Start: 2024-06-01End: 2026-12-31Target: 80Updated: 2024-11-15